Of the 100 children registered for Covid vaccine trials there, AIIMS Patna has already administered the first dose of Bharat Biotech's Covaxin on some 20, officials associated with the project have said.
Earlier in the week, NITI Aayog s Member Health, Dr V.K. Paul said: "Covaxin has been approved by the Drugs Controller General of India (DCGI) for Phase 2 and 2 clinical trials in the age group of two to 18 years. I have been told that trials will begin in the next 10-12 days."
Updated: Jun 3, 2021, 08:40 AM IST
The paediatric trials for the COVID-19 vaccine manufactured by the Bharat Biotech, Covaxin has started at Patna`s All India Institute of Medical Sciences (AIIMS). Covaxin received the Drugs Controller General of India (DCGI) nod to conduct clinical trials in children on May 11.
Dr VK Paul, Member (Health), Niti Aayog had earlier said, Covaxin has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years.
The Covaxin trials are also slated to take place in 525 subjects at various sites, including AIIMS, Delhi, and Meditrina Institute of Medical Sciences, Nagpur.
NEW DELHI: All India Institute of Medical Sciences (AIIMS) in Patna on Wednesday began clinical trials of the indigenous Covaxin for children in the age group of 2 to 18 years, according to Prasar Bharati.
Registration for the children to participate in the second phase clinical trial of the Covid-19 vaccine was made open from last week at AIIMS-Patna.
The move came after the Drugs Controller General of India (DGCI) granted permission for the phase 2-3 clinical trial of Covaxin on children. AIIMS-Patna has been selected as one of the sites for the trial along with other institutes such as AIIMS-Delhi and Meditrina Institute of Medical Sciences, Nagpur.